Idemitsu invests in European Open Innovation Venture Capital Fund from Emerald
16.11.2020 05:00:00 EET | Business Wire | Press release
Idemitsu Kosan Co.,Ltd. (Headquarters: Tokyo, Japan), has decided to invest in an open innovation evergreen fund, managed by Emerald Technology Ventures, a Swiss clean technology-focused venture capital organization (Headquarters: Zurich, Switzerland). In addition, Idemitsu has decided to establish a new open innovation promotion base in Switzerland. For new business creation, Idemitsu strengthens its efforts to accelerate innovations with start-up companies, not only in Japan, but around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201115005016/en/
The Emerald fund portfolio focuses on industrial innovations in both material chemistry and clean technologies that can help resolve social issues with improvements to energy efficiencies and reductions in carbon dioxide levels. Idemitsu’s investment in this evergreen fund and the creation of a partnership with Emerald will realize new synergies that play on Emerald’s technological expertise and market insight, as well as Emerald’s access to start-up companies in North America, Europe and Israel, together with Idemitsu’s existing technologies and cultivated business networks. Those synergies will in turn lead to the creation of a resilient business portfolio that can flexibly and tenaciously respond to changes in business conditions by incorporating technological innovations from start-up companies.
To further accelerate global open innovations, Idemitsu also plans to establish a European open innovation promotion base in the Swiss canton of Basel-Stadt.
“To resolve the priority themes in our Medium-term Management Plan*, we not only pursue maximal synergies with technologies that are related to those our corporate group has already developed, but will also stress the promotion of open innovations that build on external technologies and ideas,” said Hajime Nakamoto, Managing Executive Officer in Innovation Strategy Planning, Electronic Materials Business, Agri-Bio Business, Lithium Battery Material, Intellectual Property, and Research at Idemitsu. “This investment and the establishment of overseas bases are momentous steps forward for us. Though implementation of open innovation is a long-term objective, we, especially our young employees, drive ourselves forward to laying the foundations early.”
Idemitsu is taking on the challenge of creating new values through the promotion of global open innovation.
Notes:
* Idemitsu’s Medium-term Management Plan (FY2020-2022)
https://sustainability.idemitsu.com/en/themes/259
|
[Overview of Idemitsu Kosan Co.,Ltd.] |
|
|
Company Name |
Idemitsu Kosan Co.,Ltd. |
|
Business Description |
Sustainable supply of various forms of energy and materials |
|
Website |
|
|
[Overview of Emerald Technology Ventures] |
|
|
Company Name |
Emerald Technology Ventures |
|
Business Description |
Open Innovation Venture Capital |
|
Website |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201115005016/en/
Contact information
Public Relations Section, Idemitsu Kosan Co., Ltd.
https://www.idemitsu.com/contact/flow/index.html
Yuuka Sakata (Ms.)
yuka.sakata.1070@idss.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 15:00:00 EET | Press release
Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations mo
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release
Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 14:30:00 EET | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy. Preliminary Trial Results RLS-1496 was well-tolerated,
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 14:30:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemotherapy, radiotherapy and targeted therapies - many of which are associated with cardiovascular toxicities. Global studiesi show that heart-related complications are now the second leading cause of death in cancer survivors, after the cancer itself, accounting for
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 14:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom